Piscataway, NJ, United States of America

Kumar Balashanmuga Pabbisetty

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 12 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Squibb. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kumar Balashanmuga Pabbisetty. Retrieved from https://idiyas.com/inventor/kumar-balashanmuga-pabbisetty

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 93.3

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 15)

Average Co-Inventor Count = 9.6

ph-index = 1

Forward Citations = 11(Granted Patents)

Company Filing History:

13 out of 3,742

Bristol-Myers Squibb Compnay

Years Active: 2016-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758559 - RXFP1 agonists (2026-10-13),

2. 12709594 - RXFP1 AGONISTS (2026-08-18),

3. 12428421 - Pyrimidinones as factor XIA inhibitors (2025-09-30),

4. 11053247 - Pyrimidinones as factor XIA inhibitors (2021-07-06),

5. 10829501 - Spiroheptane salicylamides and related compounds as inhibitors of ROCK (2020-11-10),

6. 10611776 - Spiroheptane salicylamides and related compounds as inhibitors of rock (2020-04-07),

7. 10336754 - Pyrimidinones as factor XIa inhibitors (2019-07-02),

8. 10316035 - Triazolopyridine inhibitors of myeloperoxidase (2019-06-11),

9. 10287288 - Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties (2019-05-14),

10. 10273236 - Macrocyclic factor XIa inhibitors bearing heterocyclic groups (2019-04-30),

11. 9951071 - Dihydropyridone P1 as factor XIa inhibitors (2018-04-24),

12. 9920075 - Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase (2018-03-20),

13. 9777001 - Macrocycles with aromatic P2' groups as factor xia inhibitors (2017-10-03),

14. 9453018 - Pyrimidinones as factor XIa inhibitors (2016-09-27),

15. 9409908 - Dihydropyridone p1 as factor XIa inhibitors (2016-08-09),

Title: Innovations of Kumar Balashanmuga Pabbisetty in Pharmaceutical Chemistry

Introduction

Kumar Balashanmuga Pabbisetty, based in Piscataway, NJ, is an accomplished inventor with a remarkable portfolio that includes 12 patents. His innovative contributions primarily focus on pharmaceutical compounds that address various medical conditions, showcasing his expertise in the field of pharmaceutical chemistry.

Latest Patents

Among his latest inventions, Pabbisetty has developed compounds characterized as pyrimidinones functioning as selective factor XIa inhibitors. The compounds, represented in his patent, aim to treat thromboembolic and inflammatory disorders, offering new possibilities in therapeutic interventions. He also introduced spiroheptane salicylamides and related compounds that serve as inhibitors of Rho-associated protein kinase (ROCK). This invention paves the way for treatments related to cardiovascular, smooth muscle, oncological, neuropathologic, autoimmune, fibrotic, and inflammatory disorders.

Career Highlights

Kumar Balashanmuga Pabbisetty has gained valuable experience while working at Bristol-Myers Squibb Company, where he contributed significantly to pharmaceutical advancements. His extensive background in research and development in the pharmaceutical industry allows him to create impactful inventions that address pressing health issues.

Collaborations

During his career, Pabbisetty has collaborated with notable professionals such as Andrew K. Dilger and Wu Yang. These partnerships have undoubtedly enhanced his innovative capabilities and the breadth of his research endeavors.

Conclusion

Kumar Balashanmuga Pabbisetty continues to make strides in the realm of pharmaceutical inventions. With his impressive number of patents and dedication to addressing vital medical challenges, he remains a prominent figure in the field, driving forward the development of novel compounds for various disorders. His work demonstrates the essential role that inventors play in advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.